Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

88 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies.
Chung HC, Piha-Paul SA, Lopez-Martin J, Schellens JHM, Kao S, Miller WH Jr, Delord JP, Gao B, Planchard D, Gottfried M, Zer A, Jalal SI, Penel N, Mehnert JM, Matos I, Bennouna J, Kim DW, Xu L, Krishnan S, Norwood K, Ott PA. Chung HC, et al. Among authors: zer a. J Thorac Oncol. 2020 Apr;15(4):618-627. doi: 10.1016/j.jtho.2019.12.109. Epub 2019 Dec 20. J Thorac Oncol. 2020. PMID: 31870883 Free article.
Collaterals.
Zer A, Rapson Y, Stemmer SM. Zer A, et al. J Thorac Oncol. 2013 May;8(5):662-3. doi: 10.1097/JTO.0b013e3182843a10. J Thorac Oncol. 2013. PMID: 23584299 Free article. No abstract available.
Response to Yamamoto et al.
Zer A, Tsao MS, Shepherd FA. Zer A, et al. J Thorac Oncol. 2016 Oct;11(10):e129-30. doi: 10.1016/j.jtho.2016.08.130. J Thorac Oncol. 2016. PMID: 27663403 Free article. No abstract available.
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC; KEYNOTE-189 Investigators. Gandhi L, et al. N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16. N Engl J Med. 2018. PMID: 29658856 Free article. Clinical Trial.
BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors.
Dudnik E, Peled N, Nechushtan H, Wollner M, Onn A, Agbarya A, Moskovitz M, Keren S, Popovits-Hadari N, Urban D, Mishaeli M, Zer A, Allen AM, Rabinovich NM, Rotem O, Kuznetsov T, Shochat T, Roisman LC, Bar J; Israel Lung Cancer Group. Dudnik E, et al. Among authors: zer a. J Thorac Oncol. 2018 Aug;13(8):1128-1137. doi: 10.1016/j.jtho.2018.04.024. Epub 2018 Apr 30. J Thorac Oncol. 2018. PMID: 29723688 Free article.
Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data.
Dudnik E, Moskovitz M, Rottenberg Y, Lobachov A, Mandelboim R, Shochat T, Urban D, Wollner M, Nechushtan H, Rotem O, Zer A, Daher S, Bar J; Israel Lung Cancer Group. Dudnik E, et al. Among authors: zer a. Oncoimmunology. 2021 Jan 28;10(1):1865653. doi: 10.1080/2162402X.2020.1865653. Oncoimmunology. 2021. PMID: 33552685 Free PMC article.
88 results